Insulin Lispro Protamine Suspension + Insulin Glargine

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Nov 1, 2007 โ†’ Dec 1, 2009

About Insulin Lispro Protamine Suspension + Insulin Glargine

Insulin Lispro Protamine Suspension + Insulin Glargine is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00560417. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00560417Phase 3Completed
NCT00510952Phase 3Completed